Class summary at a glance.

Every drug in the Parenteral Iron Replacement class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 5tracked in Part D
CY24 Part D spend: —combined across class
Total Rx claims: —— unique beneficiaries
Generic mfrs (active): 5across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Ferumoxytol

Brand: FeraBright · — Part D claims (CY24) · First FDA approval: 2009-07-13

1 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Iron Sucrose

Brand: Venofer · — Part D claims (CY24) · First FDA approval: 2000-11-10

3 generic mfrs

Low NADAC$12.21

→

Avg plan cost$12.21

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Sodium Ferric Gluconate Complex

Brand: Ferrlecit · — Part D claims (CY24) · First FDA approval: 2011-03-01

1 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Sodium Ferric Gluconate Complex In Sucrose

— Part D claims (CY24) · First FDA approval: 2011-03-31

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Venofer (Iron Sucrose)

— Part D claims (CY24) · First FDA approval: 2021-06-25

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.